Optimizing Dosage Selection Strategies in Oncology – ASCO
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“A new report calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the ‘maximum tolerated dose’ (MTD) may be outdated, harmful to patients, and ill-suited for modern cancer therapies.
‘The Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology,’ a new report published July 24 in the Journal of Clinical Oncology, is the result of a joint collaboration between the American Society of Clinical Oncology and the Food and Drug Administration. It identifies critical shortcomings in the current MTD-centric paradigm and outlines five guiding principles for optimizing cancer therapy dosage moving forward.
Read the full report.”
More posts featuring ASCO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023